A Network Meta-Analysis of Randomized Controlled Trials to Evaluate the Comparative Efficacy of Disease-Modifying Therapies for Patients with Relapsing Multiple Sclerosis

E-poster: P047

Abstract

Findings From OLIKOS: Baseline Immunoglobulin and B-Cell Concentrations in Patients Who Switch From Ocrelizumab to Ofatumumab

E-poster: P077

Abstract

Quality of Life and Treatment Satisfaction with Ofatumumab and Other DMTs in MS

E-poster: P457

Abstract

Ofatumumab for Relapsing Multiple Sclerosis: Summary of Global 2022 NMA Update

 

Interim Results of an Open Label Study to Assess Humoral Immune Response to COVID 19 mRNA Vaccine in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

E-poster: P101

Abstract

Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data

E-poster: P109

Abstract

Evaluating Humoral Immune Response to mRNA COVID 19 Vaccines in Siponimod treated Patients with Advancing Forms of Relapsing Multiple Sclerosis: A COVID 19 Vaccine Sub study of Phase 3b EXCHANGE Trial

E-poster: P133

Abstract

Longitudinal Analysis of Adaptive Immunity Following Additional SARS-CoV-2 Vaccination in MS Patients on Anti-CD20 Therapies and Sphingosine-1-phosphate Receptor Modulators

E-poster: P141

Abstract

Early Reduction in Plasma Glial Fibrillary Acidic Protein Levels in Siponimod Treated SPMS Patients (EXPAND) Is Associated With Reduced Risk of Disability Worsening

E-poster: P017

Abstract

Patient and Nurse Preferences for the Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results From a Multicenter Survey

E-poster: P210

Abstract

Effectiveness, Safety, and Patient Reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design

E-poster: P042

Abstract